Nature Reviews Cancer

Papers
(The median citation count of Nature Reviews Cancer is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Targeting ferroptosis as a vulnerability in cancer1014
Cancer metabolism: looking forward884
Therapeutic cancer vaccines827
Systemic immunity in cancer746
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion715
The role of ROS in tumour development and progression702
Connecting copper and cancer: from transition metal signalling to metalloplasia665
Endoplasmic reticulum stress signals in the tumour and its microenvironment638
The matrix in cancer549
The metabolism of cancer cells during metastasis526
Recent advances and discoveries in the mechanisms and functions of CAR T cells520
Interleukins in cancer: from biology to therapy404
Long noncoding RNAs in cancer metastasis398
Advances in bladder cancer biology and therapy372
Exploiting senescence for the treatment of cancer369
Natural killer cells in antitumour adoptive cell immunotherapy322
Linking EMT programmes to normal and neoplastic epithelial stem cells316
Advancing targeted protein degradation for cancer therapy304
Cancer stem cell–immune cell crosstalk in tumour progression303
Targeting DNA damage response pathways in cancer279
The immunological and metabolic landscape in primary and metastatic liver cancer279
Harnessing multimodal data integration to advance precision oncology232
Autophagy in tumour immunity and therapy227
The language of chromatin modification in human cancers220
CRISPR in cancer biology and therapy213
Targeting CDK4 and CDK6 in cancer209
Designing deep learning studies in cancer diagnostics205
The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs194
Cancer nanomedicine194
Tumour fatty acid metabolism in the context of therapy resistance and obesity191
Targeting FAK in anticancer combination therapies187
Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities184
Programmed death ligand 1 signals in cancer cells183
Genetic and non-genetic clonal diversity in cancer evolution181
MYC protein interactors in gene transcription and cancer176
Liquid–liquid phase separation drives cellular function and dysfunction in cancer173
A timeline of tumour-associated macrophage biology169
Targeting the DNA damage response in immuno-oncology: developments and opportunities168
Overcoming TGFβ-mediated immune evasion in cancer165
Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data165
Antitumour immunity regulated by aberrant ERBB family signalling162
Sex disparities matter in cancer development and therapy159
Mutational signatures: emerging concepts, caveats and clinical applications155
Towards targeting of shared mechanisms of cancer metastasis and therapy resistance150
Clonal expansion in non-cancer tissues150
RNA splicing dysregulation and the hallmarks of cancer145
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer144
Stress and cancer: mechanisms, significance and future directions141
The plasticity of mRNA translation during cancer progression and therapy resistance135
Mitochondrial DNA variation and cancer132
Polyamines in cancer: integrating organismal metabolism and antitumour immunity130
Dynamics and specificities of T cells in cancer immunotherapy127
Aneuploidy as a promoter and suppressor of malignant growth127
Mechanisms of immune activation and regulation: lessons from melanoma120
Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment118
mRNA-based cancer therapeutics117
Big data in basic and translational cancer research114
Artificial intelligence in cancer research, diagnosis and therapy109
Glial and myeloid heterogeneity in the brain tumour microenvironment108
Cancer proteogenomics: current impact and future prospects105
Biology, vulnerabilities and clinical applications of circulating tumour cells104
Advances in germline predisposition to acute leukaemias and myeloid neoplasms103
Synthetic biomarkers: a twenty-first century path to early cancer detection102
Nucleotide metabolism: a pan-cancer metabolic dependency101
Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies97
Smokeless tobacco and cigarette smoking: chemical mechanisms and cancer prevention96
STAT proteins in cancer: orchestration of metabolism96
Decoding leader cells in collective cancer invasion93
Therapeutic targeting of tumour myeloid cells92
Mapping the genomic diaspora of gastric cancer91
Targeting the gut microbiota for cancer therapy91
Leukaemia: a model metastatic disease90
The coming decade in precision oncology: six riddles88
Mechanisms driving the immunoregulatory function of cancer cells84
Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment83
Acetyl-CoA metabolism in cancer76
Bacteria in cancer initiation, promotion and progression74
Targeting transcription cycles in cancer73
Developing dietary interventions as therapy for cancer71
Evolving cancer–niche interactions and therapeutic targets during bone metastasis68
Non-coding driver mutations in human cancer67
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation65
Context-dependent functions of pattern recognition receptors in cancer63
Brain cancer stem cells: resilience through adaptive plasticity and hierarchical heterogeneity60
Tissue clearing to examine tumour complexity in three dimensions60
Nonsense-mediated RNA decay: an emerging modulator of malignancy59
Cancers make their own luck: theories of cancer origins58
Insights into recent findings and clinical application of YAP and TAZ in cancer57
Disconnecting multicellular networks in brain tumours56
Leveraging the replication stress response to optimize cancer therapy52
Deubiquitinases in cancer50
Endocytosis in cancer and cancer therapy49
Tumour–host interactions through the lens of Drosophila47
Remodelling of the tumour microenvironment by the kallikrein-related peptidases46
Understanding tumour endothelial cell heterogeneity and function from single-cell omics45
3D bioprinted cancer models: from basic biology to drug development44
Solid tumours hijack the histone variant network44
Intravital imaging to study cancer progression and metastasis44
Aristolochic acid-associated cancers: a public health risk in need of global action43
Advances in PET imaging of cancer41
Epithelial and stromal co-evolution and complicity in pancreatic cancer41
Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters40
Equivocal, explicit and emergent actions of PKC isoforms in cancer39
Structural variations in cancer and the 3D genome39
Evolution and progression of Barrett’s oesophagus to oesophageal cancer38
The journey from melanocytes to melanoma37
Removing global barriers to cervical cancer prevention and moving towards elimination36
Advances in cutaneous squamous cell carcinoma34
The advent of immune stimulating CAFs in cancer33
Rethinking cancer targeting strategies in the era of smart cell therapeutics33
The biology of ependymomas and emerging novel therapies32
Oncofetal reprogramming in tumour development and progression31
The neural addiction of cancer29
Stem-like exhausted and memory CD8+ T cells in cancer28
Therapeutic resistance to anti-oestrogen therapy in breast cancer26
Dissecting metastasis using preclinical models and methods26
Innate lymphoid cells and innate-like T cells in cancer — at the crossroads of innate and adaptive immunity25
How chemokines organize the tumour microenvironment25
How protons pave the way to aggressive cancers21
Eph receptors and ephrins in cancer progression21
Metabolic pathway analysis using stable isotopes in patients with cancer20
Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity20
Bridging live-cell imaging and next-generation cancer treatment19
Defining and using immune archetypes to classify and treat cancer19
Gut instinct: a call to study the biology of early-onset colorectal cancer disparities18
Linking cell mechanical memory and cancer metastasis18
Nanotherapy: targeting the tumour microenvironment17
The dynamic role of platelets in cancer progression and their therapeutic implications17
Pathogenesis of cancers derived from thyroid follicular cells16
Learning to distinguish progressive and non-progressive ductal carcinoma in situ16
A guide to artificial intelligence for cancer researchers16
Mastering the use of cellular barcoding to explore cancer heterogeneity15
Translating p53-based therapies for cancer into the clinic13
Colorectal cancer subtyping13
Towards targeting transposable elements for cancer therapy13
New targets in triple-negative breast cancer13
Polygenic scores in cancer13
Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications12
Transfer RNAs as dynamic and critical regulators of cancer progression11
Beyond genetics: driving cancer with the tumour microenvironment behind the wheel11
Micro-engineering and nano-engineering approaches to investigate tumour ecosystems11
Addressing the mental health crisis10
EMT in chemoresistance10
Publisher Correction: Mutations and mechanisms of WNT pathway tumour suppressors in cancer10
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies10
Gut microbiome immaturity and childhood acute lymphoblastic leukaemia10
Un-Fair Skin: racial disparities in acral melanoma research9
Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma9
The role of eIF4F-driven mRNA translation in regulating the tumour microenvironment9
Combinatorial strategies to target RAS-driven cancers9
ATO stabilizes structural p53 mutants9
Fcγ receptors and immunomodulatory antibodies in cancer9
Targeting sex steroid biosynthesis for breast and prostate cancer therapy7
Multiplex protein imaging in tumour biology7
Making cancer research more inclusive7
Let’s get critical: bringing Critical Race Theory into cancer research7
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours7
Targeting cancer cell dormancy6
Porcine cancer models for clinical translation6
Overcoming hurdles in cancer immunotherapy6
Extrachromosomal DNA in cancer6
EGFR is going circular5
Decoding the basis of histological variation in human cancer5
Impact of COVID-19 on in vivo work and patient sample availability for cancer research5
Don’t blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemic5
Protein lipidation in cancer: mechanisms, dysregulation and emerging drug targets5
Peto’s paradox put to the test5
The link between vitamin D and prostate cancer5
Tertiary lymphoid structures as hubs of antitumour immunity5
Expanding oesophageal cancer research and care in eastern Africa4
Addressing systemic racism as the cancer of Black people: equity ethic-driven research4
The microbiome as a determinant of racial and ethnic cancer disparities4
SETDB1, a new target for immunotherapy4
Obesity-induced neutrophil reprogramming4
Tracing the origins of KRAS oncogene addiction4
Promoting cancer genomics research in Africa: a roadmap4
Liver metastases cultivate an immune desert4
Neutrophils: a roadblock for immunotherapy4
Bispecifics target cancers’ most wanted4
T cell drivers in NASH-HCC3
Personal regulome navigation of cancer3
Studying extrachromosomal DNA with the ecTag method3
Metastases arrive at other organs via bone3
Publisher Correction: Programmed death ligand 1 signals in cancer cells3
Cells are Us – combining research and public engagement3
Fungi in cancer: not such a ‘fun-guy’3
Long-range gene regulation in hormone-dependent cancer3
Lifestyle interventions for cancer survivors3
Cancer burden in low-income and middle-income countries3
Air pollution promotes tumorigenesis through pre-existing oncogenic mutations3
Advances in translational research of the rare cancer type adrenocortical carcinoma3
Tracking dormant disseminated tumour cells3
Reflecting on 20 years of progress3
INVADEseq to study the intratumoural microbiota at host single-cell resolution3
Tracking genome evolution following p53 inactivation2
The neuronal-metabolic interface2
Hunting down rare drug-tolerant cycling cells with Watermelon2
Stromal cells drive tumorigenesis in BRCA1 mutation carriers2
Cycling persister cells2
Guardrails for the use of generalist AI in cancer care2
Funding bodies should foster partnerships between industry and academia2
Microbiota links to immunotherapy toxicity2
Functional lineage tracing to study the clonal evolution of therapy resistance2
CAF-induced physical constraints controlling T cell state and localization in solid tumours2
Why do patients with cancer die?2
Blebs signal survival2
Naughty neutrophils2
Understanding and addressing race disparities in childhood cancer outcomes2
AR in immunotherapy2
Integrating microbiomics in cancer management2
Platelets limit liver tumours2
tRNA supply and demand2
Developmental origins shape the paediatric cancer genome2
Tumour avatars to model patients’ responses to immunotherapy2
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment2
Mechanosurveillance of tumour metastasis2
Taming TAMs in brain metastases2
Next-generation epidemiologic cohorts for cancer aetiology2
METTL3 inhibition enhances anti-tumour immunity2
Cancer therapy with antibodies2
Improving understanding of cancer in the gender diverse population2
IgA strikes twice in ovarian cancer2
Approaching cancer during pregnancy2
Quantum probes in cancer research2
Feeding latent brain metastasis1
When the tumour is at bay, the CD8+ T cells come out to play1
Educating macrophages in melanoma1
AT1 cells appear centre stage1
Impaired RNA clearance1
Lymphatic vessels in the age of cancer immunotherapy1
Resolving the spatial heterogeneity of cancer in 3D1
Shining a light on tumour behaviour1
Glycogen condensates drive tumorigenesis by trapping Hippo kinases1
Harnessing the influenza virus to fight cancer1
Bringing community to our pages1
Persistence is key1
Author Correction: Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma1
Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance1
Exploiting temporal aspects of cancer immunotherapy1
Towards cancer equity via patient outreach1
Digging for treasures in the tumour interactome1
MYC inhibition, courtesy of E. coli1
Presenting fibroblasts1
What cancer survivors can teach cancer researchers1
Epitranscriptomics of cancer microniches1
Antihistamines boost immunotherapy1
The circ du RNA1
How medical anthropology can contribute to cancer research1
Bidirectional CART.BiTE cells bring new hope1
Judith Campisi (1948–2024)1
0.10023307800293